InVivo Therapeutics CSO steps down before 1-year anniversary
InVivo Therapeutics (OTC:NVIV) chief science officer Dr. Edward Wirth resigned his post, effective Sept. 21, after just 11 months with the company.
The Cambridge, Mass.-based device maker appointed Wirth to the CSO role in October 2011, poising him to lead InVivo’s efforts to win FDA approval for human trials of its biodegradable spinal cord scaffold. There was no reason given for his departure.
NeuroTherm names new president & CEO
Wilmington, Mass.-based pain management devices maker NeuroTherm named Gregory Cash its new president & CEO, also adding him to the company’s board of directors. Cash was most recently president & CEO of HeartSine Technologies.
Ingen Tech adds trio to board
Riverside, Calif.-based Ingen Technologies (OTC:IGNT) added 3 new members to its board of directors: RC Product Development & Engineering president Richard Campbell, SomaLife Consulting executive VP Michael Cooper and SomaLife Consulting CEO David Holland.